Skip to main content

Alosetron and Eluxadoline Use: A Descriptive Analysis

    Basic Details
    Date Posted
    Thursday, July 6, 2023
    Medical Product

    In this analysis, we investigated utilization patterns of alosetron and eluxadoline. Two patient cohorts assessed these products without inclusion or exclusion requirements. Two additional cohorts assess these products with an inclusion requirement of a diagnosis of irritable bowel syndrome (IBS) in addition to an exclusion requirement of a diagnosis of intestinal ischemia.

    The study period includes data from January 1, 2010 to September 30, 2020.

    We executed this request on Merative™ MarketScan® Research Databases on August 17, 2021.

    Additional Details
    FDA Center
    Time Period
    January 1, 2010 – September 30, 2020
    Study Type
    Query Builder
    Assessment Type
    Exploratory Analyses
    Population / Cohort
    All individuals
    Data Sources
    Merative™ MarketScan® Research Databases